A common challenge for pharma is the high variability in measured outcome of drugs between clinical trials and real world use, especially in some of the costly chronic disease areas. With drug delivery data increasingly being digitized, opportunities arise to leverage IT to combine that data with other data sources (GPS, BGM/CGM, activity, nutrition, etc.), ultimately reducing the performance gaps between clinical trials and real world use. Leveraging IT goes well beyond “there is an app for this” as data needs to be collected, stored, analyzed and turned into meaningful insights for physicians, care teams and patients alike to improve the adherence. My Dose Coach is an IT solution for diabetes insulin dosing, collecting physicians’ data on titration schemes as well as the daily blood glucose and insulin data from patients to advise them according to their physican’s prescription. The solution includes a data backend, a patient app, and web access for physician and administrators to manage their clinic and patients. With an effective discussion occurring between physicians and patients, there is demand for additional data sources to be added in order to further enrich the dialogue as well as learning, allowing patients to make decisions based on these gained insights. Drug delivery efficacy is becoming an IT job requiring pharma companies to adopt new skills and capabilities in order to play in such a digital drug delivery world.

Leverage partneringONE® to identify and qualify technology leads and close the deal that expands your product lifecycle.

• Conduct more meetings at one conference than in the rest of the year
• Contact existing and potential partners prior to the conference
• Manage all your conference activities in one place
• Your meetings will be prescheduled to maximize your time on site.

A robust system integration of a prefillable syringe in an Autoinjector is critical to ensure a safe and effective drug delivery to patients. Through BD Physioject Autoinjector case study we will review the benefits of system integration and lessons learned after 8 years commercialization.

AstraZeneca is a global, science-led biopharmaceutical company and one of only a handful of companies to span the entire life-cycle of a medicine from research and development to manufacturing and supply, and the global commercialisation of primary care and speciality care medicines. Pharmaceutical Technologies & Development (PT&D) develops technologies to support products from initiation of clinical studies through to post product launch. The PT&D Innovation Strategy & External Liaison (IS&EL) team introduce new technology platforms and capabilities, improve PT&D’s readiness to support the future portfolio and works towards establishing an industry leading global capability.

Our partnering approach is to seek out collaborations that drive real progress, are founded on trust and transparency, are innovative and value-adding, and enhance our expertise.

Connected Health remains a hot topic of discussion in the drug delivery industry. However very few systems have actually made it to the market so far. Part of the reason for this is the challenge and high cost of implementing connectivity on the devices that increasingly are being used by patients for home delivery of costly and life-saving medicines. Phillips-Medisize has been delivering a range of solutions to address this problem, including the first such connected drug-device solution approved by FDA. This session will explore the technical and economic challenges, and present a range of ‘ready to use’ solutions, from low cost connectivity to reusable devices.

More than 500 meetings expected in 2018.

Be sure to sign-up early for maximum partnering and exposure in 2018!

To develop truly patient-centric products, pharmaceutical and combination products companies need to consider several factors. By keeping the technology, user needs, and patient perspective at the forefront of development, combination product developers can create a drug delivery system with an improved user experience. In this session, two seasoned combination product developers share their experiences with combining technology with patient-centered design.

The implementation and market launch of new technologies can be challenging.  Partnering with another company can often provide a faster market entry with new technology versus internally developed products.  This presentation will discuss the rationale for the Haselmeier and Common Sensing partnership, discussing how the synergy of each company’s technology and capabilities provides long term benefits to both.  We will discuss the structure of the partnership, outlining the key roles and responsibilities of each company along with the expected benefits.

We have designed peptides to selectively alter inter- and intra-protein domain interactions that can modulate epithelial cell tight junction (TJ) function to improve the oral delivery of poorly absorbed biopharmaceuticals. Two peptides, in the range of 9-11 amino acids, were designed that can target specific interfacial surfaces involved in protein-protein contacts that selectively regulate the function of TJ-associated myosin light chain phosphatase (MLCP). The local, topical application of these Permeant Inhibitor of MLCP (PIP) peptides minimizes off-target events and limits the systemic distribution of these molecules. Function of these PIP peptide was demonstrated in vitro and in vivo for the transport of several therapeutic peptides.

Brain diseases are responsible for 12% of global deaths and their treatment could benefit from the use of highly potent and specific pharmaceuticals with low inherent toxicity and immunogenicity such as neuropeptides 1. However, for neuropeptide therapies to be realised, peptides need to be able to cross the blood-brain barrier (BBB) and possess enhanced enzymatic stability to ensure adequate brain bioavailability. Lipidisation of peptides has been proven to be a useful strategy to enhance enzymatic stability and BBB permeability, while increasing the amphiphilicity of neuropeptides allows their self-assembly in well-defined nanostructures 2,3. We have developed a neuropeptide amphiphile able to self-assemble and entrap brain impermeable drugs, which; possess enhanced stability to enzymatic degradation, permeates the BBB (all human in vitro BBB model) and targets receptors overexpressed in glioblastoma cells resulting in a novel targeted nanomedicine with a strong anti-proliferative and apoptotic effects in vitro. The proposed nanomedicine can be readily translated and proof of concept in an animal model is under way. References[1] Lalatsa, A., et al. Molecular Pharmaceutics 2014, 11, 1081-1093.[2] Lalatsa, A., et al. Molecular Pharmaceutics 2012, 9, 1665-1680.[3] Lalatsa, A., et al. Journal of Controlled Release 2015, 197, 87-96.Published in - Journal of Interdisciplinary Medicine, Vol. 1, Issue 2.

Formulation of poorly soluble BCS Type 2 drugs is a topic of great industrial interest. A robust dry powder formulation platform for direct compression tableting is developed that allows increasing the solubility and dissolution rate for a wide range of drugs from diverse pharmacological classes. This platform can potentially eliminate the need for formulating poorly soluble drugs in the form of soft gel capsules or salt conjugates, offering both clinical benefits and cost-efficiency. The platform is based on the use of large surface area analogue of microcrystalline cellulose. For formulation, the technology platform utilizes the most basic industrial equipment in 2-3 straight steps and completely avoids the use of solvents, whether organic or aqueous, for drug loading. It further does not rely on expensive mesoporous inorganic carriers, which may show enhanced solubility but particle size dependent dissolution profile. Pre-clinical case studies will be presented covering two distinct pharmacological classes, viz. pain management and anti-hypertensives.